2021’s crystal ball: Six AI predictions from Aktana management that will shape a new commercial model.

Belgo-Dutch biotech Galapagos NV and U.S. partner Gilead Sciences Inc. will discontinue late-stage trials testing their experimental drug ziritaxestat in patients with pulmonary fibrosis.

In a historical move, healthcare investor giant Deerfield Management entered a second partnership with one of its academic collaborators, investing up to $130 million over the next ten years into Dana-Farber Cancer Institute to advance the development of new therapeutics and diagnostic tools for cancer patients.

Gilead Sciences Inc. decided not to pursue the U.S. Food and Drug Administration’s approval of the company’s experimental rheumatoid arthritis treatment, filgotinib, following a meeting with the health regulator.

Warren Buffett, one of America’s best-known investors, is backing multiple pharmaceutical companies developing therapies aimed at curbing the ongoing global Covid-19 pandemic.

Find out which biopharma companies are raking in the cash this week, as companies from around the globe provide updates on their financing rounds and IPOs.

Days after the U.S. Food and Drug Administration greenlit the restart of AstraZeneca’s Phase III Covid-19 vaccine trial, the U.K.-based company said the preventative medication boosts immune responses in older and younger adults against the novel coronavirus.

UCB is investing more than £1 billion ($1.29 billion) over five years to expand the company’s research and development capabilities in the U.K., which will include a transition to a newly acquired 47-acre R&D campus from Eli Lilly located in Windlesham, Surrey.

Shares of CStone Pharmaceuticals were up after Pfizer invested $200 million into the company for a nearly 10% stake to support the development of a checkpoint inhibitor aimed at the oncology market in China.

Moderna Inc. and Vertex Pharmaceuticals Incorporated announced a new strategic research collaboration and licensing agreement aimed at the discovery and development of lipid nanoparticles and mRNAs for the delivery of gene-editing therapies for the treatment of cystic fibrosis (CF).